Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03621644 · ClinicalTrials.gov registry record · NA
Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer
A NA study of Pancreatic Cancer, sponsored by Viewray.
- Active
- Registry status
- NA
- Development phase
- 133
- Enrollment target
- 13
- Study locations
NCT03621644 is a NA study of Pancreatic Cancer that is active but no longer recruiting, run by Viewray. The registered enrollment target is 133 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (66% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT03621644, a NA study of Pancreatic Cancer, is active but no longer recruiting, sponsored by Viewray.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 133 participants
- Enrollment target
- 13
- Study locations
Study Summary
High-dose magnetic resonance imaging (MRI) guided hypofractionated radiation therapy delivered using daily adaptive dose planning has been shown in a retrospective study to result in improved overall survival, relative to patients receiving lower radiation doses, in patients with locally advanced pancreatic cancer, without increasing the rate of serious gastrointestinal toxicity. The goal of the proposed trial is to investigative in a controlled, prospective manner the robustness of this outcome, and to track quality of life over a 5-year trial period.
Conditions Studied
Interventions
- RADIATION Stereotactic MRI-guided On-table Adaptive Radiation Therapy
Study Locations (13)
Florida
- University of Miami - Miami
- Miami Cancer Institute - Miami
- Orlando Health - Orlando
California
- UCLA - Los Angeles
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- Henry Ford Health Sciences - Detroit
Missouri
- Washington University - St Louis
New Hampshire
- Dartmouth-Hitchcock - Lebanon
New York
- Cornell University - New York
Oregon
- Providence Portland Cancer Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2027-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03621644
The ClinicalTrials.gov registry entry for NCT03621644 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (66% lower). The listed sponsor is Viewray, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic MRI-guided On-table Adaptive Radiation Therapy is the first listed.
NCT03621644 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03621644 about?
NCT03621644 is a clinical study titled "Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer". High-dose magnetic resonance imaging (MRI) guided hypofractionated radiation therapy delivered using daily adaptive dose planning has been shown in a retrospective study to result in improved overall survival, relative to patients receiving lower radiation doses, in patients with locally advanced pa...
What is the current status of trial NCT03621644?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 133 participants. The study started on 2019-01-01. Estimated completion is 2027-01.
What conditions does trial NCT03621644 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT03621644?
The interventions under investigation include: Stereotactic MRI-guided On-table Adaptive Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03621644?
This trial is sponsored by Viewray, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03621644 being conducted?
This trial has 13 study locations across California, Florida, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
RECRUITING · NA
-
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
RECRUITING · NA
-
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.